Used in research as a potent and selective inhibitor of c-Met kinase, showing antitumor activity in preclinical models. Demonstrates potential in targeting cancers driven by c-Met signaling pathways, particularly in non-small cell lung cancer and other solid tumors. Investigated for its ability to overcome resistance to EGFR inhibitors when c-Met activation is involved. Not approved for clinical use; primarily utilized in laboratory studies to understand kinase inhibition and cancer progression.